Novartis
NVS | NYSE
$160.20
-$0.30 (-0.19%)
At close: Nov 16, 2026, 4:00 PM ET
$160.20
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Novartis Company Profile
Company profile explainedCompany Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Vasant Narasimhan | Chief Executive Officer |
| Mukul Mehta | Chief Financial Officer |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research |
| Karen L. Hale | Chief Legal & Compliance Officer |
| Patrick Horber | President of International |
| Paul Penepent | Head of Group Financial Reporting and Accounting |
| Robert Kowalski | Chief People & Organization Officer |
| Sloan Simpson | Global Head of Investor Relations |
| Steffen Lang | President of Operations |
| Victor Bulto | President of US |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 27, 2026 | 6-K | Filing |
| Sep 08, 2026 | 6-K | Filing |
| Sep 04, 2026 | 6-K | Filing |
| Sep 01, 2026 | 6-K | Filing |
| Jul 21, 2026 | 6-K | Filing |
| Jun 11, 2026 | 6-K | Filing |
| Apr 28, 2026 | 6-K | Filing |
| Mar 18, 2026 | 6-K | Filing |
| Mar 17, 2026 | 424B5 | Filing |
Novartis
| Country | Switzerland |
| IPO Date | Nov 7, 1996 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 75,267 |
| CEO | Vasant Narasimhan |
Stock Details
| Ticker Symbol | NVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001114448 |
| CUSIP Number | 66987V109 |
| ISIN Number | US66987V1098 |
| SIC Code | 2834 |
Recent News
- 15 hours ago / zacks.comNovartis' Cosentyx Gets Positive CHMP Opinion for Adolescents With HS
- 16 hours ago / zacks.comIs Novartis (NVS) Outperforming Other Medical Stocks This Year?
- 4 days ago / zacks.comAre You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice
- 8 days ago / zacks.com3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
- 13 days ago / fool.comNovartis: 3 Key Takeaways for Long-Term Investors
- 14 days ago / zacks.com3 Stocks to Watch Following Guidance Upgrades
- 14 days ago / prnewswire.comBioArctic collaborator Novartis terminates agreement
- 15 days ago / reuters.comNovartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
- 17 days ago / seekingalpha.comNovartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach
- 18 days ago / zacks.comAll You Need to Know About Novartis (NVS) Rating Upgrade to Buy
Add to Watchlist
Select watchlists to add or remove NVS